Roth Capital lowered the firm’s price target on Reviva Pharmaceuticals (RVPH) to $3 from $7 and keeps a Buy rating on the shares. The firm cites dilution for the target cut post the company’s Q2 report. It believes Reviva’s upcoming FDA Type C meeting presents an “intriguing scenario” to buy the stock at current levels given the opportunity to bypass a second Phase 3 study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVPH:
- Reviva Pharmaceuticals price target lowered to $2 from $5 at Maxim
- Reviva Pharmaceuticals reports Q2 EPS (12c) vs. (26c) last year
- Reviva Pharmaceuticals Announces Public Offering Agreement
- Reviva Pharmaceuticals prices 20M shares at 50c in public offering
- Reviva Pharmaceuticals announces common stock, warrants offering